comparemela.com

Rr Mcl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Ibrutinib combined with venetoclaxPatients withRefractory mantle cell lymphomaPrimary analysis results fromRandomized phaseMantle cell lymphomaRr mclRelapsed refractory mantle cell lymphoma

Lisocabtagene Maraleucel in R/R MCL: Primary Analysis Results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study

Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.

Alexey danilovLisocabtagene maraleucelInternational conference on malignant lymphomaPrimary analysis resultsSeamless designPartnership withInternational conferenceMalignant lymphomaTranscend nhl 001Relapsed refractory mantle cell lymphomaLiso celRelapsed refractory mclMantle cell lymphomaTranscend nhl 001 studyRr mclTranscend nhl 001 results

vimarsana © 2020. All Rights Reserved.